Loading...

OGN ORGANON & CO Product Launches 8-K Filing

RGNN

GN

ORGANON & CO

(OGN)

2025 8-K

Show Summary

Summary

Amendments to Stock Plans

New Product Launches

Financial Statements

Board Appointment

Earnings Announcement

Management Change

Board Restructuring

Board Resignation

FDA Review Extension

Earnings Report

Merger Agreement

Earnings Release

Annual Meeting Voting Results

Private Offering of Notes

Earnings Release

Earnings Reports

Departure of Director

Earnings Reports

Earnings Reports

Earnings Release

Earnings Reports

External Links:

On May 27, 2025, Organon & Co. announced that the FDA designated its HADLIMA™ biosimilars as interchangeable with Humira®, indicating a significant step in their product lineup. This is deemed a positive advancement for the company.

AI Assistant

ORGANON & CO

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.